Literature DB >> 33751365

Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance.

Bharti Panjwani1, Vijander Singh1, Asha Rani1, Vijay Mohan2.   

Abstract

This work is focused on multi-objective optimisation of a multi-drug chemotherapy schedule for cell-cycle-specific cancer treatment under the influence of drug resistance. The acquired drug resistance to chemotherapeutic agents is incorporated into the existing compartmental model of breast cancer. Furthermore, the toxic effect of drugs on healthy cells and overall drug concentration in the patient body are also constrained in the proposed model. The objective is to determine the optimal drug schedule according to the patient's physiological condition so that the tumour burden is minimised. A multi-objective optimisation algorithm, non-dominated sorting genetic algorithm-II (NSGA-II) is utilised to solve the problem. The obtained results are thoroughly analysed to illustrate the impact of drug resistance on the treatment. The capability of optimised schedules to deal with parametric uncertainty is also analysed. The drug schedules obtained in this work align well with the clinical standards. It is also revealed that the NSGA-II optimised drug schedule with proper rest period between successive dosages yields the minimum cancer load at the end of the treatment.

Entities:  

Keywords:  Cancer chemotherapy; Cell cycle specificity; Drug resistance; Non-dominated sorting genetic algorithm II

Mesh:

Year:  2021        PMID: 33751365     DOI: 10.1007/s10928-021-09749-w

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  25 in total

1.  A novel evolutionary drug scheduling model in cancer chemotherapy.

Authors:  Yong Liang; Kwong-Sak Leung; Tony Shu Kam Mok
Journal:  IEEE Trans Inf Technol Biomed       Date:  2006-04

2.  Conflicting objectives in chemotherapy with drug resistance.

Authors:  M I Costa; J L Boldrini
Journal:  Bull Math Biol       Date:  1997-07       Impact factor: 1.758

3.  Modified fractional order IMC design based drug scheduling for cancer treatment.

Authors:  Nikhil Pachauri; Jyoti Yadav; Asha Rani; Vijander Singh
Journal:  Comput Biol Med       Date:  2019-04-25       Impact factor: 4.589

4.  Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.

Authors:  Y Shigeoka; K Itoh; T Igarashi; K Ishizawa; T Saeki; H Fujii; H Minami; S Imoto; Y Sasaki
Journal:  Jpn J Clin Oncol       Date:  2001-08       Impact factor: 3.019

5.  A mathematical model of drug resistance: heterogeneous tumors.

Authors:  J C Panetta
Journal:  Math Biosci       Date:  1998-01-01       Impact factor: 2.144

Review 6.  Role of optimal control theory in cancer chemotherapy.

Authors:  G W Swan
Journal:  Math Biosci       Date:  1990-10       Impact factor: 2.144

Review 7.  Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.

Authors:  Helen M Coley
Journal:  Cancer Treat Rev       Date:  2008-03-25       Impact factor: 12.111

Review 8.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

9.  Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Authors:  O Vainas; S Ariad; O Amir; W Mermershtain; V Vainstein; M Kleiman; O Inbar; R Ben-Av; A Mukherjee; S Chan; Z Agur
Journal:  Br J Cancer       Date:  2012-07-19       Impact factor: 7.640

10.  PKPD modeling of acquired resistance to anti-cancer drug treatment.

Authors:  Miro J Eigenmann; Nicolas Frances; Thierry Lavé; Antje-Christine Walz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-31       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.